# Correction: ContextVision AB: Result of the offer to buy back own shares

Stockholm, Dec 18, 2024

A correction is made to the press release published today, December 18, 2024, at 08.10 AM, regarding the number of shares resolved to be bought back by the company. A number of 35,722 shares were not included in the previous press release, the correct press release is as follows.

Reference is made to the stock exchange announcement on December 13th, 2024, in which ContextVision AB (publ) ("ContextVision" or the "Company") launched an offer to buy back up to 3,000,000 shares in the Company for a total amount of up to NOK 15,000,000 (the "Offer").

The application period for the Offer ended on December 17th, 2024 at 16:30 CET. Following the end of the application period, the Company has resolved to buy back 1,241,457 shares in the Company at a price of NOK 6.50 per share, amounting to a total of NOK 8,069,470.50.

All offers to sell shares with limits at or below NOK 6.50 have been fully allocated.

Allocation notifications are expected to be sent to the shareholders who tendered shares in the Offer on or about December 18th, 2024. The trade date is expected to be on or about 18 December 2024 with the settlement date expected on or about December 20th, 2024.

The settlement will be conducted on a normal delivery-versus-payment basis. Following the settlement of the Offer, the Company will own 1,241,457 shares in the Company. The Company currently has 77,367,500 shares outstanding.

This stock exchange announcement is published in accordance with the disclosure requirements in Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Richard Hallström, CFO, on the time and date provided.

**For more information, please contact:**

Carnegie AS: contextvision@carnegie.no or +47 22 00 93 40

Richard Hallström, CFO: richard.hallstrom@contextvision.com

**About ContextVision**

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X -ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.